The global cancer tumor profiling market size is expected to grow from $8.16 billion in 2021 to $9.58 billion in 2022 at a compound annual growth rate (CAGR) of 17.5%. The global cancer tumor profiling market size is expected to grow to $15.96 billion in 2026 at a CAGR of 13.6%.
What is the Global Cancer Tumor Profiling Market?
The cancer tumor profiling market consists of sales of cancer tumor profiling technologies by entities (organization, partnership, sole traders) that refer to a laboratory test that examines a sample of tumor tissue for specific genes or gene mutations (changes), proteins, or other biomarkers. Tumor profiling can help with treatment planning as well as predicting if cancer will recur or spread to other parts of the body.
Get a Sample of the global cancer tumor profiling market report
https://www.thebusinessresearchcompany.com/sample.aspx?id=6053&type=smp
What drives the Global Cancer Tumor Profiling Market?
The increasing incidences of cancer across the globe are expected to propel the growth of cancer and tumor profiling market going forward. Cancer is a disease in which some cells in the body get uncontrollably large and spread to other parts of the body. As the number of cancer cases rises, so does the demand for cancer tumor profiling, which enables doctors to determine the severity of the disease. For instance, according to the World Health Organization (WHO), there are a 19.3 million increase in cancer cases in 2020, with over 10 million fatalities worldwide. Among these new cases, lung and breast cancer accounted for 23.1% of all cancer cases. In addition, according to the International Agency for Research on Cancer (IARC), 1 in 5 individuals will develop cancer during their lifetime, and 1 in 11 women and 1 in 8 men will die from it. Therefore, the increasing incidences of cancer across the globe drive the growth of the cancer and tumor profiling market.
Get the full global cancer tumor profiling industry report here
https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report
Global Cancer Tumor Profiling Market Segments
The global cancer tumor profiling market is segmented:
By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, Stomach Cancer, Pancreatic Cancer, Thyroid Cancer, Others
By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarray, Others
By Process Type: Genomics, Proteomics, Epigenetics, Metabolomics, Others
By Application: Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, Research Applications
By Geography: The regions covered in the cancer tumor profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. Among these regions, North America accounts for the largest share in the global cancer tumor profiling market.
Cancer Tumor Profiling Global Market Report 2022provides market size and growth forecasts for the global cancer tumor profiling market, global cancer tumor profiling market share, cancer tumor profiling market segments and geographies, cancer tumor profiling market competitive landscape including leading competitors’ revenues, profiles and market shares. The cancer tumor profiling market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.
Global Cancer Tumor Profiling Industry Playersinclude F. Hoffmann-La Roche Ltd, Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., QIAGEN, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics Inc., NanoString, NeoGenomics Laboratories, Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, IMB Dx Inc., Exact Sciences Corporation (Genomic Health Inc.), Guardant Health, and Foundation Medicine Inc. Based on industry trends and company analysis, the report explains a number of strategies for companies in the market.
